Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Acromegaly Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 4255-D

    Medicare Part B Step Therapy Acromegaly Long Acting Products

    Customize your policy alerts

    Sign up for zing_health Policy 4255-D alerts

    Get alerted when Policy 4255-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of acromegaly long-acting products under Medicare Part B for Zing Health members. Non-preferred products require a clinical exception through prior authorization based on prior treatment, inadequate response, or an intolerable adverse event involving the preferred product.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Acromegaly Long Acting Products
    Policy CodePolicy 4255-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization for a non-preferred acromegaly long-acting product through the clinical exception process.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1preferred product
    3non-preferred products
    365 daysprior-use lookback
    2exception pathways
    Medicare Part B

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    benefit design

    Product-Specific Coverage Criteria

    Lanreotide Injection

    Coverage for Lanreotide Injection is provided when at least one of the following criteria is met.

    Lanreotide Injection exception pathways

    • Prior use: Member has received treatment with the requested non-preferred product in the past 365 days.past 365 days
    • Somatuline Depot intolerance: Member has had a documented intolerable adverse event to Somatuline Depot, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.

    Sandostatin LAR Depot and Signifor LAR

    Coverage for Sandostatin LAR Depot or Signifor LAR is provided when at least one of the following criteria is met.

    Sandostatin LAR Depot or Signifor LAR exception pathways

    • Prior use: Member has received treatment with the requested non-preferred product in the past 365 days.past 365 days
    • Inadequate response or intolerance to preferred product: Member has a documented inadequate response or intolerable adverse event with the preferred product, Somatuline Depot.

    Authorization and Documentation Requirements

    Prior Authorization

    Submit a clinical exception for non-preferred products

    Prior authorization is required to obtain a non-preferred acromegaly long-acting product through the clinical exception process. The review evaluates clinical circumstances that exclude use of the preferred product and may consider previous use of a product.

    Prior Authorization

    Confirm whether prior authorization is required

    Products listed as formulary or preferred may still require a clinical prior authorization review. Submit the requested clinical information when authorization is required.

    Step Therapy

    Meet the Lanreotide Injection step requirement

    For Lanreotide Injection, document that the member has received treatment with the requested product within the past 365 days, or document a qualifying intolerable adverse event to Somatuline Depot.

    Clinical Background

    Acromegaly is managed under this Medicare Part B step therapy program using long-acting injectable products. Somatuline Depot (lanreotide acetate) is the preferred product, while Lanreotide Injection, Sandostatin LAR Depot, and Signifor LAR are non-preferred products that may require a documented clinical exception through prior authorization. Step therapy applies in addition to any applicable Medicare National Coverage Determination, Local Coverage Determination, and Medicare Part B utilization management requirements.

    Key Definitions

    Preferred and non-preferred products
    Preferred productThe plan-designated first-choice product is Somatuline Depot (lanreotide acetate).
    Non-preferred productsLanreotide Injection (lanreotide acetate), Sandostatin LAR Depot (octreotide acetate for injectable suspension), and Signifor LAR (pasireotide) are non-preferred products.
    Clinical exceptionCoverage for a non-preferred product requires review of clinical circumstances that would exclude use of the preferred product and may be based on previous use of a product.
    New to treatment
    DefinitionNew to treatment means the member is receiving the non-preferred product for the first time.
    Applies toThe step therapy program applies to members who are new to treatment with the non-preferred product.

    Initial Coverage for Non-Preferred Products

    Non-preferred Product Initial Coverage

    For members requesting a non-preferred product for an FDA-approved acromegaly indication, coverage is available when the applicable product-specific exception pathway is met.

    Coverage requirements

    • FDA-approved indication: The request is for treatment of an indication that is FDA-approved for the preferred products.
    • Product-specific exception pathway

      • Lanreotide Injection: The member has received treatment with Lanreotide Injection within the past 365 days, or has had a documented intolerable adverse event to Somatuline Depot that was not an expected adverse event attributed to the active ingredient as described in the prescribing information.past 365 days for prior use

    Product-Specific Step Therapy

    StepRequested productCoverageRequirement
    1Lanreotide InjectionCovered with criteriaEither prior treatment with Lanreotide Injection within the past 365 days, or a documented intolerable adverse event to Somatuline Depot that was not an expected adverse event attributed to the active ingredient as described in the prescribing information.
    StepRequested productsCoverageRequirement
    1Sandostatin LAR Depot or Signifor LARCovered with criteriaEither prior treatment with the requested product within the past 365 days, or a documented inadequate response or intolerable adverse event with the preferred product, Somatuline Depot.
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Acromegaly Long Acting Products
    Policy CodePolicy 4255-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization for a non-preferred acromegaly long-acting product through the clinical exception process.
    SourceLink
    On This Page
    Product-Specific Coverage CriteriaAuthorization and Documentation RequirementsClinical BackgroundKey DefinitionsInitial Coverage for Non-Preferred ProductsProduct-Specific Step Therapy
    • The adverse event must not be an expected adverse event attributed to the active ingredient as described in the prescribing information.
    Step Therapy

    Meet the Sandostatin or Signifor step requirement

    For Sandostatin LAR Depot or Signifor LAR, document that the member has received treatment with the requested product within the past 365 days, or document inadequate response or an intolerable adverse event with Somatuline Depot.

    Documentation Required

    Provide Lanreotide supporting documentation

    Document treatment with Lanreotide Injection within the past 365 days, or document an intolerable adverse event to Somatuline Depot and establish that it was not an expected adverse event attributable to the active ingredient as described in the prescribing information.

    Documentation Required

    Provide Sandostatin or Signifor supporting documentation

    Document treatment with the requested Sandostatin LAR Depot or Signifor LAR within the past 365 days, or document inadequate response or an intolerable adverse event with Somatuline Depot.

    Denial Risk

    Avoid missing the Lanreotide exception criteria

    Coverage for Lanreotide Injection may be denied when the member has not used the requested product within the past 365 days and does not have a documented intolerable adverse event to Somatuline Depot that was not an expected adverse event attributable to the active ingredient.

    Denial Risk

    Avoid missing the preferred-product exception criteria

    Coverage for Sandostatin LAR Depot or Signifor LAR may be denied when the member has not used the requested product within the past 365 days and lacks documented inadequate response or an intolerable adverse event with Somatuline Depot.

    Denial Risk

    Use an FDA-approved indication

    The request must be for an indication that is FDA-approved for the preferred products. Requests for other indications do not meet this policy requirement.

    Coverage reviewCoverage for a non-preferred product is evaluated through a clinical exception review based on circumstances that may exclude use of the preferred product.
    Sandostatin LAR Depot or Signifor LAR: The member has received treatment with the requested non-preferred product within the past 365 days, or has a documented inadequate response or intolerable adverse event with the preferred product, Somatuline Depot.past 365 days for prior use